
A breakthrough in biofilm prevention for DENTAL implants + ORTHOPEDIC components
lowers risk of inflammation AND infection-related complications
Nilbax® is developed by TekCyte, an Australian surface-coating technology company addressing complex fouling and contamination challenges across medical and industrial applications
Nilbax® targets distinct healthcare risks + costs associated with DENTAL + ORTHOPEDIC implants
Nilbax® for DENTAL implants
Reduces bacterial adhesion and biofilm on dental implants + supports cleaner implant surfaces in high-risk oral environments
Nilbax® for ORTHOPEDIC components
Reduces bacterial adhesion on orthopedic components + supports safer device performance by targeting inflammation- and infection-related risks
A high-performance, passive coating designed to create a protective surface barrier on medical implants
- Reduces bacterial adhesion & biofilm formation – decreasing infection & inflammation risk
- Acts passively – no antibiotics, silver or active biological agents
- Chemically stable – commercially scalable
- Suitable for several device materials including titanium and stainless steel
- Compatible with standard sterilisation methods
- Patented & available for licensing

Nilbax™
Evidence it works
Independent laboratory testing confirms Nilbax® reduces bacterial adhesion and biofilm formation on coated titanium + anodised titanium surfaces
Studies conducted with Adelaide University: A/Prof Peter Zilm (Head, Translational Research in Oral Health Science Group, School of Dentistry) & A/Research Prof Paul H. Anderson (School of Pharmacy & Biomedical Sciences).

broad-spectrum protection
When applied to titanium, Nilbax® significantly reduces biofilm formation across a wide range of organisms.
Samples were incubated for 24 hours in static overnight cultures of Candida albicans, gram-positive or gram-negative bacteria, then stained with crystal violet to highlight the biofilm forming on each surface.
IMAGES: Biofilm stained with crystal violet shows as white; top row uncoated, bottom row NNilbax®-coated.
reducing bacterial adhesion
Nilbax® creates a barrier on the surface of dental and orthopedic implants and components, reducing the likelihood of post-procedure inflammation and infection.
Titanium samples were incubated with Staphylococcus aureus for 24 hours in static culture, washed extensively to remove loosely bound bacteria, then fixed for microscopic image analysis. The analysis confirmed a 2-log reduction in adhered bacteria on Nilbax®-coated titanium.
IMAGES: Samples photographed after washing (top) and under a scanning electron microscope at 1000x magnification (bottom).


lasting protection under flow
A flow cell moves fresh culture across the surface continuously, which is closer to conditions in the mouth than a static dish.
Anodised titanium abutments were exposed to a mixed culture of five oral bacteria (Streptococcus mutans, Actinomyces naeslundii, Veillonella dispar, Fusobacterium nucleatum and Porphyromonas gingivalis) in a flow cell for 10 days. Uncoated abutments developed dense, established biofilm, while Nilbax®-coated abutments remained largely clear, with a 5-fold average reduction in biofilm.
Anodised titanium implant posts tested under the same conditions showed a 10-fold average reduction.
IMAGES: 3D views of biofilm volume (pink), three matched samples for each surface.
integrates normally with bone
A coating that keeps bacteria off an implant must not get in the way of healing.
In a rat femoral bone model, Nilbax®-coated and uncoated titanium screws were assessed at 14, 28 and 56 days after insertion, using torsional fixation testing, peri-implant bone volume and bone mineral density.
Nilbax® showed no evidence of impaired bone integration or screw fixation in this model.
Study conducted at Adelaide University; manuscript in preparation

Global collaborations with purpose
TekCyte works with leading innovators across medical, biotech and industrial sectors to bring advanced coating science into real-world application.
We have collaborated with organisations including Saint-Gobain, Cynata Therapeutics, Alyra Biotech and Osmoflo.
Using world-leading surface technologies, the TekCyte team contributes deep technical expertise and scientific insight to a wide range of commercial projects and research collaborations, supporting both early-stage innovation and commercial-scale integration.
These collaborations reflect our reputation for high-quality, flexibility and results-driven execution in addressing complex surface challenges.
Our collaborations
Using world-leading surface technologies, the TekCyte team contributes their extensive knowledge and know-how to a diverse range of commercial projects and research collaborations.








